TriangleFOR PATIENTS · SOURCE READING
Targeted therapy
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment Option Overview / The following types of treatment are used:
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. There are different types of targeted therapy:
Source links and citations
Tyrosine kinase inhibitor. Tyrosine kinase inhibitor therapy blocks signals needed for tumors to grow. Sorafenib, lenvatinib, vandetanib, cabozantinib, selpercatinib, larotrectinib, entrectinib, and pralsetinib are used to treat certain types of thyroid cancer. New types of tyrosine kinase inhibitors are being studied to treat advanced thyroid cancer.
Protein kinase inhibitor. Protein kinase inhibitor therapy blocks proteins needed for cell growth and may kill cancer cells. Dabrafenib and trametinib are used to treat anaplastic thyroid cancer in patients with a certain mutation in the BRAF gene.
Source links and citations
See Drugs Approved for Thyroid Cancer for more information.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice